Clinical trials: Prolactinoma
Hyperprolactinemia, Prolactinoma
Treatment of Hyperprolactinemia With the Non-ergoline Dopamine Agonist Ropinirole
The purpose of this study is to evaluate the use of the non-ergoline dopamine agonist ropinirole for the treatment of hyperprolactinemia in patients with idiopathic hyperprolactinemia and prolactinomas.
- Trial name
- NCT03038308
- Testing
- Ropinirole
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Columbia University
Pituitary Adenomas, Prolactinomas
Targeted Therapy With Lapatinib in Patients With Recurrent Pituitary Tumors Resistant to Standard Therapy
This study focuses on new therapies for a challenging disease in pituitary medicine, that of aggressive pituitary tumors which have limited therapeutic options beyond standard surgical, radiotherapy, and select medical therapies…
- Trial name
- NCT00939523
- Testing
- Lapatinib
- Where
- 3 sites in United States
- Volunteers
- 9 people
- Sponsor
- Cedars-Sinai Medical Center
Non-functioning Pituitary Adenomas, Prolactinomas
Response to Cabergoline and Pasireotide in Non-functioning Pituitary Adenomas and Resistant Prolactinomas
There are no available medical treatment options for patients with non-functioning pituitary adenomas (NFPA) or with resistant prolactinomas to dopamine agonists (DA) who are not cured by surgery.
- Trial name
- NCT01620138
- Testing
- Pasireotide, cabergoline
- Where
- Brazil
- Volunteers
- 21 people
- Sponsor
- Universidade Federal do Rio de Janeiro